Alectinib is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to Crizotinib.
Alectinib as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Name | Alecinix |
Generic Name | Alectinib |
Formulation | Capsule |
Available Pack Size | 3x10's Alu-Alu |
Available Strength | 40 mg |